In particular, treatment with bortezomib reduced the levels of Fanconi Anemia (FA) factors BRCA1/2 and FANCD2, and proved effective to induce DNA damage and cell death in combination with melphalan (103). This evidence concerns the gene FANCD2 and Friedreich ataxia.